<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The role of <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (MTX), given with <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> (CS), after HLA-identical sibling bone marrow transplantation needs to be defined </plain></SENT>
<SENT sid="1" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo>, 80 patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> were enrolled in a prospective randomized trial </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> were given BuCy conditioning </plain></SENT>
<SENT sid="3" pm="."><plain>The 40 patients in the CS arm received CS 3 mg/kg/day intravenously, with subsequent oral dosing </plain></SENT>
<SENT sid="4" pm="."><plain>Patients in the CS + MTX arm received, in addition to CS, MTX intravenously, 15 mg/m2 on day 1, and 10 mg/m2 on days 3, 6, and 11 </plain></SENT>
<SENT sid="5" pm="."><plain>Transplantation-related mortality was low in both groups of patients (13 vs 11% for CS vs CS + MTX groups, P = 0.94) </plain></SENT>
<SENT sid="6" pm="."><plain>The CS group had a significantly higher frequency of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (56 vs 32%, P = 0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>After a median follow-up of 22.1 months (5.1-47.8 months), three of 30 vs 10 of 28 patients with <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>/<z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) in CS group vs CS + MTX group relapsed (P = 0.01) yielding better overall survival for patients with <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> treated with CS (P = 0.02) </plain></SENT>
<SENT sid="8" pm="."><plain>After HLA-identical sibling bone marrow transplantation, immunosuppression with CS, with or without MTX, resulted in similarly low transplantation-related mortality </plain></SENT>
<SENT sid="9" pm="."><plain>In <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, decreased relapse with patient survival prolongation was observed in the CS group </plain></SENT>
</text></document>